PerSimiO offers a bone-strength prediction technology validated by ex-vivo experiments on a large cohort of bones. PerSimiO develops Simfini, a SaaS simulation tool that can provide patient-specific bone analysis, predict the risk of fracture, and select an orthopedic implant for optimal fit. The company has developed four products, Simfini-TUMOR, Simfini-OSTEO, Simfini-IMPLANT, and Simfini-DIABETES, which will identify patients at high risk of contralateral hip fracture and enable better planning, treatment, and oversight to minimize the risk. The company's products target the diagnosis and treatment of a variety of diseases including osteoporosis, metastatic tumors, and injuries that weaken the bone. The products are designed to optimize treatment and improve outcomes at a reduced cost. PerSimiO has conducted clinical trials at three medical centers in Israel.

PerSimiO (פרסימיו)

PerSimiO (פרסימיו)